Norton Rose Fulbright (Toronto)

Brian Daley

Norton Rose Fulbright (Toronto)

Brian Daley practises intellectual property law, with a focus on patents, trademarks and litigation at the trial, appellate and Supreme Court levels. He has particular experience in regulatory matters and litigation involving mechanical, medical device and pharmaceutical patents. He worked as an engineer for four years before studying law. Mr. Daley is often retained to act as lead counsel on complex patent litigation and has been recognized as one of Canada’s leading lawyers in this area. This includes patent infringement actions as well as summary proceedings under Canada’s Patented Medicines (Notice of Compliance) Regulations. He has also successfully defended damages claims brought by generic pharmaceutical companies who claim to have been kept off the market because of proceedings brought by patentees. Mr. Daley recently led a team that obtained an important victory in the Federal Court of Appeal in defence of a patent infringement action against a Canadian company specializing in dry eye diagnosis and management. He also defeated motions for interim and interlocutory injunctions. Mr. Daley is a frequent presenter to professional organizations and companies as well as a contributor to publications in the intellectual property and regulatory fields in North America and Europe. He is the pharmaceutical and life sciences international business group leader within the life sciences and healthcare industry group in Canada.


Linked authors

Norton Rose Fulbright (Toronto)
Norton Rose Fulbright (New York)
Norton Rose Fulbright (Brussels)
Norton Rose Fulbright (Paris)
Norton Rose Fulbright (Brussels)


22 Bulletin

Brian Daley, Christopher Guerreiro, David Yi The Canadian Competition Authority publishes a revised version of its IP enforcement guidelines with particular importance for pharmaceutical companies


This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. On March 13, the Competition Bureau published a revised version of its IP Enforcement Guidelines (IPEGs). The IPEGs clarify the Bureau’s approach to conducting (...)

Send a message